Jansitin

Sitagliptin, the active ingredient in Jansitin, is a DPP-4 inhibitor presented as a tablet for oral use. It helps improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glucose regulation.

- Type 2 diabetes mellitus (monotherapy): improves fasting and post‑prandial blood glucose levels when used with diet and exercise. - Type 2 diabetes mellitus (combination therapy): used together with metformin or other oral antidiabetics to achieve target HbA1c. - Adults with inadequate glycemic control on existing therapy: provides an additional mechanism to lower glucose without causing weight gain.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat. - Nausea: occasional stomach upset. - Diarrhea: loose stools. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Joint pain: unexplained arthralgia. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: elevated liver enzymes. - Severe hypoglycemia: when combined with insulin or sulfonylureas.

Before prescribing Jansitin, clinicians should consider several safety aspects.

- Renal impairment: adjust dose or avoid in severe renal dysfunction. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: monitor closely for recurrent episodes. - Elderly patients: observe for hypoglycemia when used with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycemia. - Sulfonylureas (e.g., glipizide): heightened hypoglycemia potential. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin effectiveness. - Diuretics: can affect glucose control, monitor blood sugar. - Warfarin: monitor INR as sitagliptin may alter anticoagulant response.